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Abstract
Background: Methylsulfonylmethane (MSM) is a nutraceutical compound which has been indicated to counteract
osteoarthritis, a cartilage degenerative disorder. In addition, MSM has also been shown to increase osteoblast
differentiation. So far, few studies have investigated MSM role in the differentiation of mesenchymal stem cells
(MSCs), and no study has been performed to evaluate its overall effects on both osteogenic and chondrogenic
differentiation. These two mutually regulated processes share the same progenitor cells.
Methods: Therefore, with the aim to evaluate the effects of MSM on chondrogenesis and osteogenesis, we
analyzed the expression of SOX9, RUNX2, and SP7 transcription factors in vitro (mesenchymal stem cells and
chondrocytes cell lines) and in vivo (zebrafish model). Real-time PCR as well Western blotting, immunofluorescence,
and specific in vitro and in vivo staining have been performed. Student’s paired t test was used to compare the
variation between the groups.
Results: Our data demonstrated that MSM modulates the expression of differentiation-related genes both in vitro
and in vivo. The increased SOX9 expression suggests that MSM promotes chondrogenesis in treated samples. In
addition, RUNX2 expression was not particularly affected by MSM while SP7 expression increased in all MSM
samples/model analyzed. As SP7 is required for the final commitment of progenitors to preosteoblasts, our data
suggest a role of MSM in promoting preosteoblast formation. In addition, we observed a reduced expression of the
osteoclast-surface receptor RANK in larvae and in scales as well as a reduced pERK/ERK ratio in fin and scale of MSM
treated zebrafish.
Conclusions: In conclusion, our study provides new insights into MSM mode of action and suggests that MSM is a
useful tool to counteract skeletal degenerative diseases by targeting MSC commitment and differentiation.
Keywords: Methylsulfonylmethane, Mesenchymal stem cells, Chondrocytes, Osteoblasts
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: mariateresa.valenti@univr.it
1Department of Medicine, University of Verona and Azienda Ospedaliera
Universitaria Integrata Verona, Verona, Italy
Full list of author information is available at the end of the article
Carbonare et al. Stem Cell Research & Therapy          (2021) 12:326 
https://doi.org/10.1186/s13287-021-02396-5
Background
Methylsulfonylmethane (MSM) is a popular dietary sup-
plement, suggested for relieving joint/muscle pain,
thanks to its anti-inflammatory properties. MSM is a
natural member of the methyl-S-methane compounds,
and it can be synthetically produced through the oxida-
tion of DMSO with hydrogen peroxide (H2O2) [1]. In
in vitro studies, it has been demonstrated that MSM in-
hibits the nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-κB) [2, 3] as well as p65-S536 phos-
phorylation [4]. Hence, NF-κB inhibition results in the
reduced expression of IL-1, IL-6, tumor, and necrosis
factor-α (TNF-α) [5, 6]. In addition, MSM reduces the
expression of nitric oxide synthase (iNOS) and
cyclooxygenase-2 (COX-2) [7].
MSM has been suggested as a nutraceutical compound
to counteract osteoarthritis [8]. Osteoarthritis (OA) is a
degenerative disease characterized by pain, affecting cartil-
age homeostasis by inducing its degradation and impairing
matrix neo-synthesis by chondrocytes [9]. Chondrocytes
derive from mesenchymal stem cell (MSCs) condensation
and differentiation induced by the transcription factor
SOX9 [10, 11]. When the balance between degradation
and synthesis of cartilage matrix proteins is affected, in-
flammation and OA disease arise [12]. Cheleschi et al. by
performing an in vitro study demonstrated that MSM has
beneficial effects on chondrocytes exposed to interleukin
(IL)-1β, most likely by modulating the NF-κB pathway [8].
In another in vitro study, MSM was shown to increase
osteoblast differentiation through the Jak2/STAT5b path-
way [13]. It is well known that MSC osteogenic differenti-
ation is induced by the upregulation of the master gene
RUNX2, which in turn transactivates its downstream part-
ner SP7 (Osterix), SP7 then promotes the expression of
osteogenic genes such as SPARC (osteonectin), SSP1
(osteopontin), COL1A1 and COL1A2 (collagen type I),
and BGLAP (osteocalcin) [14]. Other in vitro studies sug-
gested that MSM increases osteogenic differentiation by
inducing BMP2 [15] or transglutaminase-2 (TG2) [16].
MSM influence on the commitment and differentiation of
mesenchymal cells appears evident on the basis of these
findings. SOX9 and RUNX2 interact in progenitor cells
and can affect their respective transactivation in a recipro-
cal way [17]. Regulation of RUNX2 and SOX9 occurs at
the transcriptional and posttranscriptional levels: phos-
phorylation, acetylation, and ubiquitination can modulate
their activity [18–20]. The temporal and spatial distri-
bution and overlapping expression of RUNX2 and
SOX9 occurring in embryogenesis show a coordinated
interplay between these two genes in bone formation
[21–23]. Importantly, it has been demonstrated that
SOX9 induces RUNX2 degradation; hence, it plays an
important role in controlling mesenchymal stem cells
differentiation fate [17].
With the aim to deepen our knowledge about MSM
effects on both chondrogenesis and osteogenesis, we
have investigated the molecular modulation following
MSM supplementation during the differentiation in both
in vitro models (mesenchymal stem cells and chondro-
cytes) and in vivo models (larvae and adult zebrafish).
Methods
Metylsulfonylmethane
Metylsulfonylmethane (MSM) (Artrosulfur; Laborest
S.r.l, Assago, MI, Italy) was used at the concentration of
20 mM as previously reported [24, 25].
XTT test
Cell viability was evaluated by using the Cell prolifera-
tion kit II (XTT Chemicon) as previously described [26].
Six replicates in three independent experiments were
tested.
Cell cultures
Human mesenchimal stem cells (hMSC, PromoCell,
Heidelberg, Germany) were plated at a density of 5 ×
104 cells and cultured with mesenchymal stem cell
growth medium (PromoCell) or osteogenic differenti-
ation medium or chondrogenic differentiation medium
(PromoCell, Heidelberg, Germany) and incubated at
37°C in a humidified atmosphere with 5% CO2. Differen-
tiating cells were then used for further analyses. Human
chondrocytes (HCH), PromoCell, Heidelberg, Germany)
were plated at a density of 5 × 104 cells and cultured
with DMEM 10% FBS medium at 37°C with 5% CO2.
IL1β (1 ng/mL) was added to HCH cells to mimic OA
conditions, as previously reported [26]. Three independ-
ent experiments were performed for each condition.
Zebrafish
Zebrafish experiments were performed at the CIRSAL
(Interdepartmental Centre of Experimental Research
Service) of the University of Verona, Italy. The animal
protocol was approved by the Italian Ministry of Health
Directorate-General for animal health and veterinary
medicinal products (authorization n. 662/2019-PR of 16/
09/2019). The embryos were obtained from natural
spawning of nacre adults (ZFIN database ID: ZDB-ALT-
990423-22), according to standard protocols [27], and
staged according to Kimmel [28]. Zebrafish embryos
were grown at 33°C in water containing 20-mM MSM
from 2 days post fertilization (dpf). Zebrafish embryos
were treated with MSM up to 1 week (experimental end-
point, 9 dpf) or 2 weeks (experimental endpoint, 16 dpf).
At the end of the treatment, zebrafish embryos were eu-
thanized and collected for molecular analyses as de-
scribed below. Calcein staining was performed as
previously reported [29]. Imaging was performed using
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Leica M205FA fluorescence microscope (Leica Microsys-
tems, Wetzlar, Germany). Stained areas were quantified
by using the ImageJ software, as previously reported [29].
Adult zebrafish (15–20 months) were grown in water
containing 20 mM of MSM for 14 weeks. At the experi-
mental endpoint, zebrafish were euthanized and col-
lected for staining and molecular procedures, as
reported below.
Total RNA extraction and reverse transcription
Pellets from cell lines or zebrafish samples were col-
lected, stored at −80°C and processed for RNA extrac-
tion with a “RNeasy® protect mini kit” (Qiagen, Hilden,
Germany) following the manufacturer’s instruction.
RNA samples were quantified using the Qubit™ RNA HS
assay kit” (Invitrogen, Carlsbad, USA). RNA (1 mg) was
reverse transcribed using the first-strand cDNA synthe-
sis kit (GE Healthcare, Little Chalfont), according to the
manufacturer’s instruction. miRNAs were extracted by
using miRNeasy Mini Kit (Qiagen, Hilden, Germany),
according to the manufacturer’s instructions. First-
strand complementary DNA (c-DNA) synthesis was per-
formed using the TaqMan™ MicroRNA Reverse Tran-
scription Kit (Applied Biosystems, CA, USA) according
to the manufacturer’s protocol. RNA, microRNAs, and
cDNA samples were stored at −80°C until use.
Real-time PCR
To investigate gene expression modulation, we performed
real-time PCR analyses as reported previously [30].
Briefly, predesigned, gene-specific primers, and probe
sets for each gene (RUNX2, hs00231692_m1; OSTERIX
(SP7), hs00541729_m1; COLLAGEN, TYPE I, ALPHA 2
(COL1A2), hs01028956_m1; OSTEONECTIN (SPARC),
hs00234160_m1; OSTEOPONTIN (SPP1), hs00167093_
m1, SOX9, hs01107818_m1; COMP, hs004359-m1;
COL2A1, hs00264051_m1; B2M, hs999999_m1 (house-
keeping); GAPDH, 0802021 (housekeeping); sox9a,
Dr03112282_m1; col2a1a, Dr03099270_m1; miR-146b-
5p, 474220; RNU44, 001094) were obtained from assay-
on-demand gene expression products (Thermo Fisher
Corporation, Waltham, MA, USA). In addition, the fol-
lowing custom primer sets (Invitrogen, Carlsbad, CA,
USA) were also used: runx2a (fw GACGGTGGTG
ACGGTAATGG, rv TGCGGTGGGTTCGTGAATA),
runx2b (fw CGGCTCCTACCAGTTCTCCA, rv CCAT
CTCCCTCCACTCCTCC), rank (fw GCACGGTTAT
TGTTGTTA, rv TATTCAGAGGTGGTGTTAT), and
as housekeeping gene actb1 (fw CCCAAAGCCAACA-
GAGAGAA, rv ACCAGAAGCGTACAGAGAGA).
Ct values for each reaction were determined using
TaqMan SDS analysis software (Applied Biosystems;
Foster City, California, USA) as reported previously. To
calculate relative gene expression levels between
different samples, we performed the analyses by using
the 2−ΔΔCT method as previously reported [30].
Immunofluorescence
Immunofluorescence analyses were performed as
previously reported [30]. Briefly, cells were fixed and
processed according to the manufacturer’s protocols.
Primary antibodies for RUNX2 and osteocalcin
(sc74495, Santa Cruz, Dallas, Texas, USA) were diluted
according to the manufacturer’s instruction in antibody
dilution buffer and incubated overnight at 4°C. Slides
were then incubated with the secondary antibodies goat
mouse fluorescein conjugated (cat. Ap124f, Millipore,
Burlington, Massachusetts, USA). Nuclear staining was
performed by ProLong™ Gold Antifade Mountant with
DAPI. The staining was analyzed using a Leica (Wetzlar,
Germany) TCS SP5 AOBS microscope. To express data
in a semiquantitative way, six different fields were ana-
lyzed for each sample, in three independent experiments
with about 80–100 total cells.
Western blotting
Protein levels were separated by SDS Page and investi-
gated by Western blot analyses as previously reported
[31]. Briefly, proteins were extracted by RIPA buffer
(Thermo Fisher Scientific, Waltham, MA, USA) and
protein concentration was established by BCA assay
(Thermo Fisher Scientific, Waltham, MA, USA). After
protein separation by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS PAGE), proteins
were transferred onto polyvinylidene difluoride (PVDF)
membranes (Thermo Fisher Scientific, Waltham, MA,
USA). PVDF membranes were then probed with the pri-
mary (Aggrecan (BC-3), Thermo Fisher Scientific; β-
actin (BA3R), Thermo Scientific; ERK (13F5), Cell Sig-
naling; p_ERK (D13.14.4E), Cells Signaling) and second-
ary antibodies (Anti-mouse (Cell Signaling, 7076); Anti-
rabbit (Cell Signaling 7074)). Signals were detected using
a chemiluminescence reagent (ECL, Millipore, Burling-
ton, MA, USA) according to the manufacturer’s instruc-
tions. Images were acquired by a LAS4000 Digital Image
Scanning System (GE Healthcare, Little Chalfont, UK).
The Densitometric analysis was performed by Image-
Quant software (GE Healthcare, Little Chalfont, UK).
Proteins optical density was normalized to β-actin.
Alizarin Red Staining in in vitro experiments
To evaluate calcium deposition in differentiating osteo-
genic cells, we performed Alizarin red staining as previ-
ously described [30]. Briefly, after 21 days of culture in
osteogenic medium, cells were fixed with 70% ethanol
and washed with water. Then, cells were stained with 40
mM Alizarin red S for 5 min at pH 4.1 and rinsed for 15
min with 1x phosphate-buffered saline. The stained area
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was quantified by using ImageJ software (NIH, Bethesda,
MD, USA) as previously reported [30]. Six independent
experiments were performed.
Zebrafish staning
Calcein staining in zebrafish larvae was performed as pre-
viously reported [29]. Imaging was performed using Leica
M205FA fluorescence microscope (Leica Microsystems,
Wetzlar, Germany). The stained area was quantified by
using the ImageJ software, as previously reported [29].
Bone and cartilage staining was performed on adult
(>1 year old) zebrafish according to Sakata-Haga et al.
[32], strictly following their “RAP System” protocol.
Briefly, euthanized fish were immersed into the FIXA-
TIVE (5% formalin, 5% Triton X-100, 1% potassium hy-
droxide (KOH) and gently rocked for 12 h at room
temperature (RT)). Then, we proceeded either to the
cartilage staining step for cartilage-only/double staining
or directly to the bone staining step for bone-only stain.
For cartilage staining, specimens were immersed into C-
STAINING SOLUTION (70% ethanol, 20% acetate,
0.015–0.02% alcian blue) overnight at 20°C, then washed
in C-STAINING MEDIUM (containing 1% Triton X-
100) overnight at 20°C and washed with 50–70% etha-
nol. For cartilage-only staining, the protocol proceeded
directly to clearing and stock steps. For cartilage and
bone double staining, the protocol proceeded to the
bone staining step. Briefly, for bone staining, specimens
were immersed into B-STAINING MEDIUM (20%
ethylene glycol and 1% KOH) and then in “B-STAINI
NG SOLUTION (0.05% alizarin red S, 20% ethylene gly-
col, 1% KOH) overnight at 20°C. The specimens were
then washed with clearing solution (20% Tween 20, 1%
KOH) while gentle rocking for 12h, and the stocking
was performed in glycerol 100%. All needed solutions
were prepared as indicated in Sakata-Haga et al. [32].
The stained area was quantified by using the Image J
software, as previously reported [29].
Statistical analysis
Results were expressed as mean ± S.E. Student’s paired t
test was used in order to compare the variation in a vari-
able between two groups. Differences were considered
statistically significant with p < 0.05. The statistical ana-
lyses were performed using GraphPad Prism software
program (version 8.3; GraphPad Software).
Results
MSM improves chondrogenesis in vitro and in vivo
To evaluate the effects of MSM in chondrogenesis, we
cultured mesenchymal stem cells with and without
MSM during chondrogenic differentiation. MSM
addition to chondrogenic medium did not affect cells
number during the differentiation period (Fig. 1A).
Instead, we observed the upregulation of the chondro-
genic transcription factor SOX9 (Fig. 1B) and of
COL2A1 (collagen type II) expression (Fig. 1C) after 3,
7, and 14 days of chondrogenic differentiation.
Increased SOX9 expression was also observed in chon-
drocytes cultured for 7 days in the presence of MSM
(Fig. 1D). In addition, MSM supplementation restored
the negative effects of IL-1β on chondrocytes. In fact,
MSM counteracted SOX9 downregulation as well as
Sestrin 1 and COMP reduced expression induced by IL-
1β (Fig. 1D). Accordingly, the production of aggrecan, a
cartilage specific proteoglycan protein, increased in
chondrocytes in the presence of MSM, and this effect
was appreciable also in chondrocytes treated with IL-1β
(Fig. 1E). The upregulation of chondrogenic genes was
observed in MSM-treated zebrafish larvae after 7 (9 dpf)
(Fig. 1F) and 14 (16 dpf) days (Fig. 1G) of treatment. We
thereafter analyzed the effects of MSM treatment on
middle-aged zebrafish (15–20 months corresponding to
36–48 years of human age) and observed increased
chondrocyte-specific Alcian blue staining in treated zeb-
rafish compared to control (Fig. 2A).
The upregulation of chondrogenic genes was observed
after 14 days in fin (Fig. 2B) and in scale (Fig. 2C) of
MSM-treated zebrafish. Therefore, as aggrecan plays an
important role in cartilage maintenance, we investigated
MSM effects on aggrecan production. In particular, we
analyzed the protein levels in fin and we observed an in-
creased production in MSM-treated zebrafish compared
to controls (Fig. 2D). On the contrary, we did not ob-
serve a significantly increased production in zebrafish
scale upon MSM treatment (Fig. 2D).
MSM promotes osteoblast maturation
Considering that chondrogenesis and osteogenesis are
intertwining processes, we evaluated the effects of MSM
in MSCs during osteogenic differentiation. As shown in
Fig. 3A, after 3 and 7 days of osteogenic differentiation,
respectively, we observed a reduced number of differen-
tiating cells. Therefore, we analyzed the expression of
osteogenic transcription factors RUNX2 and its down-
stream partner SP7. As shown in Fig. 3B, we observed
the upregulation of SP7 in MSM treated cells, whereas
RUNX2 expression levels were unchanged after 3 days
of osteogenic differentiation. Subsequently, after 7 days
of differentiation RUNX2 gene expression was reduced
in MSM treated cells, while SP7 higher expression per-
sisted. RUNX2 protein levels were consistently un-
changed after 3 days of osteogenic differentiation
(Fig. 3C) and significantly reduced after 7 days (Fig. 3D)
in MSM-treated cell nuclei. MSM effects on osteogenic
differentiation persisted also after 14 and 21 days. As
shown in Fig. 4, the expression of RUNX2 was reduced
and the expression of osteoblast maturation related
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Fig. 2 MSM increases chondrogenic gene expression in middle-aged zebrafish. Alcian blue staining was enhanced in MSM-treated zebrafish (A)
and the expression of chondrogenic genes was increased in fin (B) and in scale (C) after 14 days of treatment. Aggrecan protein levels increased
in MSM-treated zebrafish fin (D) while no difference was observed in scale (D) (a: control fin; b: treated fin; c: control; d: treated scale).
*p<0.05; **p<0.01
Fig. 1 MSM improves chondrogenesis. MSM addition did not affect the cells number (A); it upregulated the chondrogenic transcription factor
SOX9 (B) and COL2A1 expression (C) during chondrogenic differentiation. MSM enhanced SOX9 expression in chondrocytes and restored the
negative effects of IL-1β (D). MSM supplement increased the production of aggrecan by chondrocytes, even in the presence of IL-1β (E) (a:
control; c: MSM treated; c: IL-1β + MSM treated). MSM upregulated the expression of chondrogenic genes in zebrafish larvae after 7 (9 dpf) (F)
and 14 (16 dpf) (G) days of treatment. *p<0.05; **p<0.01
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genes, e.g., SPARC and SPP1, as well as the number of
osteocalcin-positive cells increased in MSM-treated cells
after 14 days of osteogenic differentiation (Fig. 4A, B).
Therefore, after 21 days of differentiation, we observed
an increased calcium deposition, evaluated by alizarin
red staining, in cells treated with MSM (Fig. 4C).
MSM enhances runx2b gene expression in zebrafish
larvae
In order to confirm the effects of MSM on osteogenic
maturation, we analyzed the osteogenic markers in zeb-
rafish larvae after 7 and 14 days of treatment in the pres-
ence of 20-mM MSM. In particular, zebrafish larvae at 2
days after fertilization (dpf) were treated with or without
MSM for 7 or 14 days. After 7 days of treatment, we ob-
served increased expression of runx2b and sp7 genes
and reduced tnfrsf1b (homolog of human RANK) gene
expression (Fig. 5A). To evaluate the direct effects of
MSM on bone formation, we quantified bone
mineralization by calcein staining. Fluorescence density
was observed under microscopic inspection and analyzed
by digital methods. Figure 5B shows higher bone mineral
density in MSM-treated larvae compared to untreated
larvae. Increased expression of runx2b and sp7 and re-
duced expression of tnfrsf1b were confirmed after 14
days of MSM treatment (Fig. 5C). In addition, we also
observed the increased expression of col1a1 gene. Bone
mineralization evaluated by calcein staining was higher
in MSM-treated zebrafish compared to untreated zebra-
fish after 14 days of treatment too (Fig. 5D).
Increased bone mineralization, evaluated by alizarin
red staining (ARS), was observed also in adult zebrafish
treated with MSM for 14 days (Fig. 6A). As shown in
Fig. 6B, a more intense ARS and an increased percentage
of positive ARS staining area was observed in MSM-
treated zebrafish compared to untreated zebrafish
(Fig. 6C). In adult zebrafish, we also analyzed the osteo-
genic gene expression and we observed different gene
modulation in fin and scale samples, respectively. As
shown in Fig. 7A, runx2a was downregulated in fin of
MSM-treated adult zebrafish. On the contrary, we ob-
served increased runx2b and reduced tnfrsf1b gene ex-
pression in scales of MSM treated zebrafish (Fig. 7B).
To understand the different osteogenic genes modula-
tion, we analyzed Alcian blue and alizarin red staining
areas for the evaluation of cartilage and calcium depos-
ition, respectively. As observed in Fig. 7C, a more pro-
nounced Alcian blue area was present in fin of MSM-
treated zebrafish compared to control. This finding is
consistent with the increased aggrecan levels observed
previously in fin of MSM-treated zebrafish. However, we
also observed an increased alizarin red staining area in
Fig. 3 Effects of MSM in the early phase of osteogenic differentiation. After 3 and 7 days of osteogenic differentiation a reduced number of
differentiating cells was observed (A). In MSM-treated cells SP7 gene expression was upregulated after 3 and 7 days of differentiation whereas
RUNX2 was downregulated after 7 days of differentiation (B). RUNX2 protein levels were similar after 3 days of osteogenic differentiation (C) and
significantly lower after 7 days of differentiation (D) in nuclei of MSM treated cells. *p<0.05; **p<0.01
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them. On the contrary, Alcian blue staining was weak in
scale of both control and treated zebrafish (Fig. 7D)
while MSM increased calcium deposition, evaluated by
alizarin red staining (Fig. 7E).
In order to evaluate a possible MSM-epigenetic effect,
we analyzed the modulation of miR146b that in humans
has been observed to be involved in mesenchymal stem
cells differentiation. As shown in Fig. 8A, miR 146b ex-
pression was reduced in both fin and scale treated with
MSM. Furthermore, as extracellular signal-regulated kin-
ase (ERK) is involved in both osteogenic and chondro-
genic commitment, we analyzed the ERK activation
pathway in fin and scale of MSM-treated zebrafish. As
shown in Fig. 8B, we observed increased levels of ERK
and a reduction of pERK as well as of pERK/ERK ratio
in both fin and scale of MSM-treated zebrafish.
Discussion
In the last decades, human lifespans have been increas-
ing; consequently, aging-related diseases such as osteo-
porosis and osteoarthritis have been increasing in turn.
Therefore, the characterization and testing of com-
pounds capable of reducing the degenerative effects of
aging-related disorders is an important challenge. In this
context, some studies have indicated that MSM may be
useful to counteract inflammation-related diseases
typical of the aging process. The interest in evaluating
MSM effects on progenitor cells should be clear, since
mesenchymal stem cells are the precursors of chondro-
cytes and osteoblasts, the cells which build the cartilage
and bone, respectively, tissues which are mainly dam-
aged by the aging process. Nevertheless, a few studies
are available, which focused on evaluating the effects of
MSM on osteogenic differentiation [24, 25, 33, 34] or on
preventing cartilage degradation [35–38]. These studies
showed that MSM is capable of enhancing osteogenic
differentiation as well as of preventing chondrocytes
degradation. However, no study has ever been per-
formed to evaluate MSM overall effects on progenitor
cells and to understand how MSM may promote both
osteogenic and chondrogenic differentiation. This is a
particularly relevant aspect, since osteogenesis and chon-
drogenesis originate from the same progenitor cells and
are highly regulated processes [39].
In our approach to understand the effects of MSM on
both chondrogenic and osteogenic processes, we ob-
served an increased chondrogenic differentiation in
MSM-treated MSCs. In fact, we observed the upregula-
tion of the chondrogenic transcription factor SOX9, as
well as the increased expression of COL2A1, the cartil-
age ECM marker protein, upon differentiation. The up-
regulation of SOX9 was also observed in chondrocytes
Fig. 4 Effects of MSM in the osteogenic maturation. RUNX2 gene expression was reduced while the expression of SPARC and SPP1 (A), as well
the number of osteocalcin positive cells (B) increased in MSM-treated cells after 14 days of osteogenic differentiation. After 21 days of
differentiation calcium deposition, evaluated by alizarin red staining (ARS), increased in cells treated with MSM (C). *p<0.05; **p<0.01
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treated with MSM. In addition, we observed the in-
creased expression of SOX9, Sestrin 1, and COMP, the
cartilage oligomeric matrix protein [40], also in chondro-
cytes treated with IL-1β, thus confirming MSM protect-
ive role against chondrocyte degradation. It has been
demonstrated that Sestrins (sesn) expression is sup-
pressed in chondrocytes of osteoarthritic cartilage. Ses-
trins increase chondrocyte survival under stress
conditions: sesn1 and sesn2 counteract oxidative stress
damage by activating the Nrf2 (nuclear factor erythroid
Fig. 5 MSM modulates gene expression in zebrafish larvae. Increased expression of sp7 gene and reduced tnfrsf1b gene expression in larvae at 9
dpf (A). The fluorescence density produced by calcein staining was higher in larvae after 7 days of MSM treatment compared to untreated larvae
(B) (a: control; b: MSM treated). Increased runx2b, sp7, col1a1, and reduced tnfrsf1b expression observed after 14 days of MSM treatment
compared to control (C). Bone mineralization evaluated by calcein staining was higher in MSM-treated larvae compared to untreated larvae after
14 days of treatment as well (5D) (a: control; b: MSM treated). *p<0.05; **p<0.01
Fig. 6 MSM increases mineral deposition in middle-aged zebrafish. Alizarin red staining (ARS) in adult zebrafish untreated (a) and treated (b) with
MSM for 14 days. A Magnification 4×. Increased percentage of the positive ARS staining area in MSM-treated zebrafish (b) compared to untreated
zebrafish (a). C Magnification 20×. *p<0.05;
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2-related factor 2)-Keap1 (Kelch-like ECH-associated
protein 1) pathway [41]. Accordingly, in our study,
MSM increased the expression levels of ACAN (aggre-
can) in chondrocytes even in the presence of IL-β1,
compared to controls. Such finding is noteworthy as
aggrecan depletion predisposes to cartilage erosion [42].
In order to investigate whether MSM induces ACAN ex-
pression also in vivo, we evaluated the effects of MSM
treatment in adult middle-aged zebrafish. Interestingly,
we observed increased aggrecan levels in fin of treated
zebrafish, but aggrecan expression was not likewise af-
fected in scale. Therefore, our results confirmed that
MSM induces chondrogenic differentiation in MSCs and
that it counteracts IL1β-negative effects on chondro-
cytes. In addition, increased aggrecan levels in MSM-
treated adult zebrafish fins suggest that MSM enhances
cartilage matrix synthesis. The more pronounced aggre-
can synthesis in fin is likely due to a higher number of
progenitor cells in fin compared to scale. It is well
known that fin, which is composed by multiple bony
rays, contains nerves, blood vessels, and mesenchymal
cells [43] whereas scale contains bone-forming cells (os-
teoblasts) and bone-resorbing cells (osteoclasts) [44].
MSM treatment affected osteogenic differentiation
both in vitro and in vivo. We observed increased expres-
sion of RUNX2-induced genes, whereas RUNX2 own ex-
pression was reduced in MSM-treated cells. The number
of MSCs was reduced as well. SP7 expression increased
during osteogenic route in MSM-treated samples. Since
SP7 is mandatory for the final commitment of progeni-
tors to preosteoblasts [45], our data suggest a role of
MSM in promoting pre-osteoblast formation. The in-
creased percentage of osteocalcin-positive cells, as well
as calcium deposition increase evaluated by AR staining
in MSM-treated cells, suggest MSM role in promoting
osteoblasts maturation rather than osteogenic commit-
ment. The induction of osteogenic maturation was ob-
served also in the zebrafish model where increased
calcein staining was observed after 7 and 14 days of
treatment. Interestingly, we observed the increased gene
expression of runx2b whereas runx2a was not affected
after 14 days of MSM supplementation. Flores et al.
demonstrated that runx2b is expressed in the vertebral
column and in the fin in a juvenile fish and that runx2a
is expressed in mesenchymal cells during caudal fin re-
generation [46]. Therefore, the higher modulation of
Fig. 7 MSM modulates gene expression in middle-aged zebrafish. Runx2a gene expression was downregulated in fin of MSM treated adult
zebrafish (A); runx2b expression increased while tnfrsf1b expression decreased in scales of MSM-treated zebrafish compared to controls (B).
Stronger Alcian blue as well as alizarin red staining areas were observed in fin of MSM-treated zebrafish (b) compared to control (a) (C);
Magnification 4×. The Alcian blue staining was weak in scales of both control (a) and treated (b) zebrafish (D) whereas a stronger alizarin red
staining area was observed in scales of MSM-treated zebrafish (E); Magnification 40×. *p<0.05
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runx2b versus runx2a observed in MSM-treated zebra-
fish suggests the effects of MSM on mature osteoblasts
rather than on MSC commitment consistently with the
RUNX2 downmodulation observed in in vitro experi-
ments with mesenchymal stem cells.
Runx2b regulates SP7/osterix and osteocalcin expres-
sion indicating its central role in skeletal development
[47, 48]. The increased osteogenic maturation was ob-
served in MSM-treated adult zebrafish; a different gene
expression pattern was observed in fin or scale of MSM-
treated zebrafish. The increased runx2b and reduced
tnfrsf1b expression observed in scale but not in fin re-
flect (as for aggrecan seen above) the different cellular
composition of the two structures, i.e., the prevalence of
osteoblasts and osteoclasts in scale. However, further
more prolonged treatment, demonstrated increased
runx2b expression even in fin. The reduced pERK and
pERK/ERK ratio together with the increased ERK levels
suggest the inhibition of Mitogen-activated protein ki-
nases (MAPKs), the proteins involved in ERK phosphor-
ylation [49]. As the reactive oxygen species (ROS)
activate MAPK pathways [50], we speculate that the re-
duced ERK phosphorylation might be a consequence of
ROS reduction due to MSM treatment. In fact, it is well
known that MSM reduces mitochondrial ROS gener-
ation [51]. Interestingly, we observed a reduced miR146b
expression in MSM-treated fin and scale. The miR-146
family is highly conserved between fish and humans, and
it shares the same seed sequence [52]. In humans, it has
been demonstrated that miR146b is downregulated in
both bone marrow stem cell (BMSC) chondrogenesis
[53] and osteogenesis [54]. In addition, it has been dem-
onstrated that miR146b promotes adipogenesis too [55].
Our finding therefore suggests an epigenetic effect of
MSM. In addition, our study reports for the first time
the involvement of miR146b in the differentiation of
mesenchymal stem cells in zebrafish.
Ultimately, our results demonstrate that MSM modu-
lates the expression of genes involved in chondrogenic
and osteogenic differentiation, likely by acting on path-
ways involved in oxidation processes. Our findings also
stimulate interesting ideas for future explorations such
as evaluating MSM effects on adipogenesis, a process
highly related to osteogenesis.
Conclusions
These findings provide new insights into the mechanism
of action of MSM supplementation on bone and cartil-
age differentiation and strengthen the rationale for MSM
supplementation in patients with osteoarticular disorders
as a complementary therapeutic intervention targeting
mesenchymal stem cells differentiation.
Fig. 8 MSM affects miR146b expression and ERK signaling. MiR 146b expression was reduced in both fin and scale treated with MSM (A).
Increased ERK levels and reduced pERK levels and pERK/ERK ratio were observed in both fin and scale of MSM-treated zebrafish; a: control fin; b:
treated fin; c: control scale; d: treated scale (B). A schematic graphic showing as MSM promotes chondroblast progenitors and pre-osteoblast
maturation by reducing ERK phosphorylation (C).
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